miR-10a was found to be downregulated in FLSs of human RA patients, which could accelerate NF-κB activation by targeting interleukin-1 receptor-associated kinase 4 (IRAK4), TGF-beta-activated kinase 1 (TAK1), and β-transducing repeat-containing protein 1 (BTRC) [29]. The gene discussed is NFKB1; the disease is rheumatoid arthritis.